Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307

OBJECTIVE: To evaluate safety, tolerability, seizure frequency, and regional variations in treatment responses with the AMPA antagonist, perampanel, in a large extension study during up to 3 years of treatment. METHODS: Patients ≥12 years old with partial-onset seizures despite treatment with 1–3 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Krauss, Gregory L, Perucca, Emilio, Ben-Menachem, Elinor, Kwan, Patrick, Shih, Jerry J, Clément, Jean-François, Wang, Xuefeng, Bagul, Makarand, Gee, Michelle, Zhu, Jin, Squillacote, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Full-Length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283992/
https://www.ncbi.nlm.nih.gov/pubmed/24867391
http://dx.doi.org/10.1111/epi.12643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283992/
https://www.ncbi.nlm.nih.gov/pubmed/24867391
http://dx.doi.org/10.1111/epi.12643

Ejemplares similares